Matsumoto Koji, Ando Masashi, Yamauchi Chikako, Egawa Chiyomi, Hamamoto Yasushi, Kataoka Masaaki, Shuto Takashi, Karasawa Kumiko, Kurosumi Masafumi, Kan Norimichi, Mitsumori Michihide
Hyogo Cancer Center, Division of Medical Oncology, Akashi, Hyogo, Japan.
Jpn J Clin Oncol. 2009 Jan;39(1):22-6. doi: 10.1093/jjco/hyn124. Epub 2008 Nov 12.
A nationwide survey was performed to investigate the current patterns of care for brain metastasis (BM) from breast cancer in Japan.
A total of 351 survey questionnaires were sent to community or academic breast oncologists who were members of the Japanese Breast Cancer Society as of December 2005. The questionnaire consists of 40 multiple choice questions in eight categories.
Of 240 institutions sent survey questionnaires, 161 (67.1%) answered; 60% of institutions answered with '<5' patients with BM every year; almost half (83 of 161) screened for BM in asymptomatic patients; surgical resection was rarely performed, as ~75% of institutions (118 of 160 institutions) answered 'none or one case of surgery per year'; 27% (41 of 154) preferred stereotactic radiosurgery (SRS) over whole-brain radiotherapy (WBRT) as the initial treatment in all cases, although ~70% (100 of 154) of them answered 'depend on cases'. The preference for SRS over WBRT mainly depends on the impressions of breast oncologists about both safety (late normal tissue damage and dementia in WBRT) and efficacy (better local control by SRS). Eighty-one percent (117 of 144) of institutions did not limit the number of SRS sessions as far as technically applicable.
SRS is widely used as the first choice for BM from breast cancer in Japan. Considerable numbers of Japanese breast oncologists prefer SRS over WBRT as the initial treatment for BM. A randomized trial comparing SRS and WBRT is warranted.
开展一项全国性调查,以探究日本目前对乳腺癌脑转移(BM)的治疗模式。
共向截至2005年12月为日本乳腺癌学会成员的社区或学术性乳腺肿瘤学家发送了351份调查问卷。该问卷由八类40个多项选择题组成。
在被发送调查问卷的240家机构中,161家(67.1%)做出了回复;60%的机构回复称每年BM患者数“<5”例;几乎一半(161家中的83家)对无症状患者进行了BM筛查;很少进行手术切除,因为约75%的机构(160家机构中的118家)回复称“每年无手术或仅1例手术”;27%(154家中的41家)在所有情况下都更倾向于立体定向放射外科治疗(SRS)而非全脑放射治疗(WBRT)作为初始治疗,尽管其中约70%(154家中的100家)回复称“取决于具体病例”。SRS相较于WBRT的偏好主要取决于乳腺肿瘤学家对安全性(WBRT导致的晚期正常组织损伤和痴呆)和疗效(SRS更好的局部控制)的看法。81%(144家中的117家)的机构在技术可行的情况下不限制SRS疗程的次数。
在日本,SRS被广泛用作乳腺癌BM的首选治疗方法。相当数量的日本乳腺肿瘤学家更倾向于将SRS而非WBRT作为BM的初始治疗方法。有必要开展一项比较SRS和WBRT的随机试验。